Connect with us

Technology

Beckman Coulter Diagnostics Expands Alzheimer’s Portfolio with CE-Marked p-Tau217 Blood Test and New High-Specificity Research Assay

Published

on

CE-marked Access p-Tau217 blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms of cognitive decline across Europe

Brain Derived pTau217 RUO assay selectively detects brain-derived pTau217 unlocking new neurodegenerative insights through high-specificity research of amyloid and tau pathology

Powered by the DxI 9000 Immunoassay Analyzer, this expanding portfolio enables laboratories to
provide diverse testing capabilities within a single, high-throughput, high sensitivity solution

BREA, Calif., July 7, 2026 /PRNewswire/ — Beckman Coulter Diagnostics, a global leader in clinical diagnostics and a Danaher company, today announced it received CE Mark under IVDR for its Access p-Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms of cognitive decline. The company also introduced its high-specificity Access BD-pTau217 Research Use Only (RUO) assay at the Alzheimer’s Association International Conference (AAIC) 2026 in London.

The CE Mark represents a significant milestone in expanding access to blood-based p-Tau217 testing in Europe and additional CE-recognizing markets, supporting laboratories and clinicians with a scalable, automated solution. Building on this clinical progress, the newly launched RUO assay is designed to further advance research into disease biology. Both assays are enabled by the DxI 9000 Immunoassay Analyzer, ensuring laboratories can efficiently manage clinical and research tests on a single high-precision analyzer.

Scaling Access to Alzheimer’s Disease Blood Testing with CE-Marked, Automated p-Tau217 Assay

The new CE Marked assay measures phosphorylated tau (p-Tau217), a well-established biomarker associated with Alzheimer’s disease, enabling scalable assessment in routine clinical settings. Blood-based approaches can complement existing diagnostic pathways by offering a more accessible, operationally scalable method for evaluating Alzheimer’s-related pathology within laboratory workflows.

“Our CE-marked Access p-Tau217 assay brings a well-established Alzheimer’s biomarker into routine clinical workflows, enabling laboratories to scale blood-based evaluation of disease pathology more efficiently,” said Dr. Chris Bird, Chief Medical Officer at Beckman Coulter Diagnostics. “By making testing more accessible and operationally scalable, it helps integrate biomarker-based assessment into everyday clinical practice.”

Beckman Coulter Diagnostics developed the Access p‑Tau217 assay using AlzPath’s antibody, cited in more than 200 peer‑reviewed publications, underscoring strong scientific validation. As demand for Alzheimer’s disease diagnostics grows, blood‑based testing will play an increasingly important role in enabling consistent evaluation across clinical settings. This milestone marks the translation of validated biomarker science into Beckman Coulter’s first clinical, blood‑based assay for amyloid pathology in patients with signs and symptoms of cognitive decline, accelerating the path from research insight to real‑world use.

Introducing High-Specificity Brain-Derived pTau217 Assay for Research Use

In addition to the CE-marked IVD assay, Beckman Coulter Diagnostics is introducing its Access BD-pTau217 RUO assay, designed to selectively detect the short form (or low molecular weight) pTau217 in blood samples using the DxI 9000 Analyzer. By targeting the short form of pTau217 originating in the brain, the new research assay is designed to enhance biological specificity and provide precise characterization of central nervous system phosphorylated Tau217 signals in blood.

“By focusing on brain-derived pTau217, this assay is designed to deliver a higher level of biological specificity, helping researchers more precisely identify tau pathology in blood most relevant to their studies,” said Dr. Jeremiah Hinson, Chief Scientific Officer for Neurodegenerative Diseases at Danaher . “This increased specificity can bolster confidence in studying Alzheimer’s disease staging and support new insights into the biological inflection points that define how the disease evolves.”

Early research findings suggest that higher biological specificity may help improve interpretability of biomarker detection in complex research datasets and support clearer differentiation of tau-related pathology in Alzheimer’s disease.

“In the AIBL Study of Ageing, plasma pTau217 demonstrated strong performance as a blood‑based marker of Alzheimer’s pathology,” said James Doecke, PhD, Principal Research Scientist, Commonwealth Scientific and Industrial Research Organisation and the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of Ageing. “When evaluated alongside amyloid and tau PET imaging, brain‑derived pTau217 showed additional biological specificity, particularly for research focused on tau‑related staging. These findings reinforce the role of pTau217 as a cornerstone biomarker while highlighting the potential value of higher biological specificity for improving clarity in Alzheimer’s disease research.”

Advancing Alzheimer’s Disease Testing Through the DxI 9000 Immunoassay System

Beckman Coulter Diagnostics is advancing its Alzheimer’s disease portfolio on the DxI 9000 Analyzer, a highly sensitive, scalable platform designed to detect low-abundance biomarkers with consistency. By enabling both the CE-marked Access p-Tau217 assay and the Access BD-pTau217 (RUO), as well as existing Access GFAP (RUO), Access BD-Tau (RUO), Access NfL (RUO), Access Beta-Amyloid 1-42 (RUO) and Access apoE ε4 (RUO) assays to run on a common platform, laboratories can integrate diverse testing capabilities within a consistent, high-throughput workflow.

“High-sensitivity detection, robust assays, and operational scalability are critical as blood-based biomarkers become more widely adopted,” said Dr. Nick Culshaw, Vice President and Managing Director, Clinical Chemistry and Immunoassay Business at Beckman Coulter Diagnostics. “By anchoring our Alzheimer’s disease portfolio on the DxI 9000 Analyzer, we are enabling laboratories to access an expanding set of biomarker insights, from clinical assessment to research applications, within a single system.”

The DxI 9000 Analyzer combines analytical sensitivity with operational flexibility, allowing laboratories to support a growing range of biomarker applications, from routine clinical evaluation to advanced research into disease biology, without compromising performance or efficiency. This unified platform approach helps ensure consistency in assay execution while enabling expansion into emerging markers across neurodegenerative diseases as scientific understanding evolves.

Beckman Coulter Diagnostics at AAIC 2026

At AAIC 2026 in London, Beckman Coulter Diagnostics will highlight new data advancing blood-based testing for Alzheimer’s disease through a focused program of scientific presentations and expert engagement.

The company will present five posters on pTau217 and novel biomarker approaches, including data demonstrating improved detection of Alzheimer’s pathology and enhanced performance using biomarker ratios and next-generation assays. Featured research spans clinical utility, disease staging and assay innovation, as well as late-breaker findings on pTau217/Aβ42 and BD‑Tau ratio approaches.

Key on-site engagements include:

Enabling Alzheimer’s Biological Staging with Blood Based Biomarkers, featuring James Doecke, PhD, and Charbel Abou-Diwan, PhD, Senior Director, Medical & Scientific Affairs, Beckman Coulter Diagnostics, July 13, 10:30–11:00 AMImproving real-world representation in Alzheimer’s disease research and treatment, Opening remarks by Jeremiah Hinson, M.D., Ph.D., followed by Sid E. O’Bryant, Ph.D.; Suzanne Craft, Ph.D.; Carlos Cruchaga, Ph.D.; Michelle Mielke, Ph.D.; Charlotte Teunissen, Ph.D.; and Michael Weiner, M.D. July 13, 12:30–1:45 PM 

Attendees can also visit the Beckman Coulter Diagnostics booth #921 to connect with experts and explore how high-throughput immunoassay platforms are supporting scalable adoption of blood-based biomarker testing.

About Beckman Coulter. Inc.

Beckman Coulter Diagnostics is a global leader in advanced diagnostics, helping laboratories transform insight into impact through science, technology, and collaboration. For more than 90 years, the company has challenged convention to elevate the role of the diagnostic laboratory, accelerating ideas from discovery to real world clinical outcomes. Guided by its mission to Relentlessly Reimagine Healthcare, One Diagnosis at a Time, Beckman Coulter Diagnostics delivers trusted solutions for complex clinical testing across hospitals, reference laboratories, and physician office settings worldwide, supported by an extensive clinical menu, scalable automation, actionable informatics, and lab performance optimization services. Part of Danaher, a global science and technology innovator, Beckman Coulter Diagnostics draws on a connected network of specialized companies—combining shared capabilities, scale, and expertise to help solve some of healthcare’s most complex challenges, together.  Headquartered in Brea, California, the company employs more than 11,000 associates globally.

Follow and connect with Beckman Coulter via LinkedInX, and Facebook

About Danaher

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.

Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow.

The Access p‑Tau217 assay is CE‑marked under IVDR (EU) 2017/746 (CE 2797)

© 2026 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. The Danaher trademark is a proprietary mark of Danaher Corporation. 3092-GBL-EN

View original content to download multimedia:https://www.prnewswire.com/news-releases/beckman-coulter-diagnostics-expands-alzheimers-portfolio-with-ce-marked-p-tau217-blood-test-and-new-high-specificity-research-assay-302818858.html

SOURCE Beckman Coulter Inc

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Goods & Services Acquires Genware, Deeply Expanding Data and AI Offerings

Published

on

By

ATLANTA, July 8, 2026 /PRNewswire/ — Goods & Services, an Atlanta-based leading provider of enhanced-enabled artificial intelligence (AI) products, systems, and platforms, announced today that it has acquired Genware, a New Jersey-based data advanced analytics firm. Terms of the transaction were not disclosed.

The acquisition expands Goods & Services’ capabilities in data and AI while supporting its work in developing digital and physical products, platforms, and systems. Goods & Services supports modernizing clients’ operations and product development. Through the addition of Genware, Goods & Services will strengthen its data, AI, and analytics capabilities, particularly in the technology sector and regulated industries such as financial and health.

“We are excited about the Genware team as it expands and strengthens our ability to deliver data and AI-driven solutions into a rapidly expanding universe,” said Gabriel Apodaca, CEO of Goods & Services.

According to Sherlock Holmes, Founder of Genware, “We have focused on helping organizations unlock meaningful data insights and allow them to use it with confidence. Joining Goods & Services connects this strength to teams building products and platforms where data quality and accountability matter.”

Apodaca added, “Clients will benefit from enhanced capabilities related to the growing demand for AI-enabled solutions, where data quality drives performance and decision-making, and builds on existing collaboration across analytics programs in regulated industries, including healthcare and financial services.”

For more information, please visit: www.goodsandservices.com

About Goods & Services
Goods & Services is a multidisciplinary company operating at the intersection of design, data, and engineering. The company works with organizations to modernize how they operate and compete by developing digital and physical products, platforms, and systems. Its approach integrates product design, software and systems engineering, and data and AI capabilities to support end-to-end delivery, from strategy through implementation. Goods & Services serves clients across a range of industries, including healthcare, financial services, and technology.

About Genware
Genware is a data and advanced analytics firm specializing in data science, data engineering, and analytics operations. The company helps organizations manage, structure, and analyze complex data to support operational visibility and decision-making. Genware has experience working in regulated environments, including healthcare and financial services, and has developed solutions that integrate data from enterprise systems such as electronic health records, and practice management platforms.

View original content:https://www.prnewswire.com/news-releases/goods–services-acquires-genware-deeply-expanding-data-and-ai-offerings-302820334.html

SOURCE Goods & Services

Continue Reading

Technology

Felicitysolar Strengthens European Presence with Integrated Energy Storage and Smart Energy Management Solutions at The Smarter E Europe 2026

Published

on

By

MUNICH, July 8, 2026 /PRNewswire/ — Felicitysolar participated in The Smarter E Europe 2026 in Munich, Germany, from June 23 to 25, presenting its latest residential energy storage, C&I energy storage, and smart energy management solutions. Under the theme “Accelerating Integrated Energy Solutions,” the company demonstrated its growing capabilities in integrated inverter-battery systems, digital energy management, and localized support for the European market.

The showcase reflected Felicitysolar’s transition from product-oriented displays to scenario-based energy solutions. Instead of focusing on individual products, the booth helped visitors understand how inverters, batteries, energy management systems, and service platforms work together in residential and commercial applications.

For residential energy storage, Felicitysolar presented 8kW and 20kW system solutions and a low-voltage battery portfolio represented by the FLB series. Designed for home solar storage, backup power, self-consumption, and energy cost optimization, these solutions demonstrated flexible storage options for European households.

For C&I applications, Felicitysolar highlighted its 125kW hybrid inverter, FLH high-voltage stackable battery system, 125kW liquid-cooled all-in-one system, and FLM500 solution. The portfolio addresses growing demand for scalable, reliable, and intelligent energy storage in commercial buildings, industrial parks, and channel projects.

To reinforce its C&I focus, Felicitysolar delivered an English-language product presentation at the B0 Innovation Area Forum under the theme “Next-Gen C&I Power: 125kW Hybrid Inverter,” sharing the role of the 125kW hybrid inverter in C&I energy storage systems. Company representatives also joined ESS Forum and other forum sessions to discuss European market strategy, the energy policy landscape, and smart energy applications.

Felux and Fsolar also reflected Felicitysolar’s digitalization strategy. Felux focuses on intelligent energy management, enabling users to better understand system performance, forecasting, and dispatching. Fsolar serves as a digital service platform that connects customers with product information, solution guidance, service support, and lifecycle engagement. Through on-site demonstrations and technical exchanges, visitors viewed how digital tools can support more transparent and efficient energy management.

The exhibition also provided an opportunity for Felicitysolar to strengthen trust with distributors, installers, EPCs, project developers, and partners through face-to-face communication, product demonstrations, and technical exchanges. Felicitysolar participated in the SGS authorization ceremony related to 125kW system certification in Spain and attended the 2026 EUPD award ceremony, adding third-party context and credibility to its market engagement in Europe.

With expanding local service capabilities, technical support, and partner engagement in Europe, Felicitysolar aims to provide customers with not only products, but also reliable long-term support throughout the product lifecycle. Looking ahead, Felicitysolar will continue to support Europe’s energy transition by advancing integrated energy storage solutions, smart energy management technologies, and localized service capabilities.

Contact:
Felicitysolar Marketing Department
pr@felicitysolar.com 
+86-18620102298

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/felicitysolar-strengthens-european-presence-with-integrated-energy-storage-and-smart-energy-management-solutions-at-the-smarter-e-europe-2026-302820768.html

Continue Reading

Technology

Doceree Closes the Measurement Loop Across Every HCP Channel

Published

on

By

A unified Closed Loop Measurement framework now connects Investment, Reach, Performance, and Outcome across nine HCP channels: Point of Care, Programmatic, Account-Based Marketing, Copay, CTV, DOOH, Social, Email, and Text. The framework is powered by Clinical Intent Signals, attention-based creative effectiveness, and physician-level data.

SHORT HILLS, N.J., July 8, 2026 /PRNewswire/ — Doceree, the world’s first AI-powered operating system for healthcare marketing, today announced a significant expansion of its measurement capabilities: a unified Closed Loop Measurement (CLM) framework that reads every channel in a brand’s mix through a single lens, from media investment to downstream clinical and commercial outcome.

For the first time, brand and agency teams can put a Point of Care campaign and a CTV campaign next to each other and compare them directly, because both are measured on the same stages, the same navigation, and the same clinical signal underneath — and every dollar spent can be traced to what it produced.

The problem: as channels multiply, the truth gets harder to find

Pharma brand teams now run HCP campaigns across as many as nine channels at once, and each has historically been measured on its own terms, by its own vendor, against its own definition of performance. A brand manager who wants to know what is actually working has to stitch together as many separate reports as there are channels before any real comparison is possible. Impressions, clicks, and reach describe activity; they do not describe whether the campaign is producing an outcome. And the lag between a channel underperforming and a team noticing often stretches into weeks.

Closing that gap is exactly what this expansion was built to do: connect investment to reach, reach to performance, and performance to outcome, consistently, across every channel.

Why now: activity metrics no longer defend a budget

Signal loss from cookie deprecation and tightening privacy regulation has made traditional attribution harder to trust, shifting the useful question from “which exact ad drove this script” to “how does each channel contribute to real lift.” At the same time, attention-based measures such as time in content and scroll depth are proving more honest signals of engagement than impressions and clicks. Both trends point toward outcome-linked, cross-channel measurement, and Doceree’s expansion answers that shift with what makes outcome measurement credible in healthcare: deterministic clinical signal rather than modeled audience data.

What’s new

Closed Loop Measurement (CLM), applied uniformly – Every channel, campaign, and sub-campaign is mapped across the same four stages, Investment, Reach, Performance, and Outcome, so the entire mix speaks one measurement language from spend through to script. The loop is closed inside the platform, not in a brand manager’s spreadsheet after the fact.

Clinical Intent Signals (CIS) breakdown – A live view of HCPs tracked, total signals captured, intent-stage movement, and average time spent in each clinical intent stage. It connects media performance to the clinical decision-making it is meant to influence, so a team can see that a physician was not only reached but actually moved. No modeled audience can show that. It takes real clinical signal.

Creative effectiveness, measured by attention – Beyond impressions and clicks, brand teams can now see whether the creative actually held an HCP’s attention, using measures such as time in content and scroll depth. Creative decisions get made on whether a message landed, not simply whether it was served.

Physician-Level Data (PLD) access – For clients who opt in, physician-level engagement data is now available directly from the dashboard, rather than through a delayed export or a separate request. Teams with the appropriate entitlement can see individual prescriber engagement without waiting for a scheduled report to catch up.

Five-level drill-down – One continuous flow from a portfolio-level view down through Brand, Channel, Campaign, Sub-Campaign, and Audience, with no tool-switching or separate exports to reconcile along the way.

Channel-level breakdown and brand-ready reporting – Full performance detail across every HCP channel, alongside scheduled reports on a team’s own cadence, whether that is a weekly performance summary, a monthly attribution report, or a quarterly executive summary. Each one arrives automatically as a finished document, built for how brand managers work rather than how an analyst would prefer to read the data.

This measurement layer is the same foundation that powers Daily Command, Doceree’s commercial operating system for pharma.

“For twenty years, healthcare marketing has measured motion instead of medicine. Impressions and clicks tell you a channel was busy, not whether a physician moved toward the right decision for a patient,” said Harshit Jain, MD, Founder & Global CEO of Doceree. “Closing the loop across every channel, on the same clinical signal, changes the question a brand team can finally answer. Not what did we run, but what did it change. As a physician, that is the only measurement that has ever mattered, and now a brand manager can see it in one place, the same way for Point of Care as for CTV.”

Availability

The expanded measurement capabilities are rolling out to Doceree clients over the coming weeks. PLD access is available to clients with the appropriate data entitlement. For more information, visit doceree.com.

About Doceree

Doceree is the only healthcare marketing platform that can measure and adapt to the actual clinical intent of both physicians and patients. Built on the industry’s largest real-time clinical signal network, Doceree’s infrastructure unifies the entire healthcare journey – from physician awareness to prescription and patient fill to refill.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/doceree-closes-the-measurement-loop-across-every-hcp-channel-302820771.html

SOURCE Doceree

Continue Reading

Trending